Are Dementia Patients Sleeping Better with Cannabis?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Sleep disturbance is one of the most common and distressing symptoms in dementia, affecting both patients and their caregivers. From nighttime wandering to agitation and reversed sleep patterns, poor rest can worsen confusion and caregiver stress. In recent years, researchers and families have started asking whether medical cannabis might help improve sleep quality, but evidence remains early and inconsistent.

According to NICE guidance NG144, cannabis-based medicinal products (CBPMs) are not approved for dementia and should only be prescribed for specific conditions such as severe epilepsy or spasticity linked to multiple sclerosis. Dementia remains outside of these national recommendations. However, small-scale studies and caregiver observations have suggested potential benefits for sleep and agitation when cannabinoids are used under medical supervision.

What The Research Shows

Evidence from international studies provides mixed but interesting findings. In a 2022 Frontiers in Aging Neuroscience study, older adults with dementia who received oral THC: CBD treatments showed calmer sleep and less agitation, according to caregiver reports. No major side effects were observed, though researchers emphasised the need for longer trials.

A 2025 Israeli cohort study reported that low-dose cannabinoid oils improved sleep duration and reduced night-time restlessness in dementia care settings. Caregivers described fewer episodes of wandering and easier settling at night. Similar findings were mentioned in Health Canada’s 2023 report, which noted that many older adults using cannabis oil under supervision reported “better overall sleep continuity.”

Despite these reports, national bodies such as NHS England and the MHRA stress that dementia remains an unlicensed indication. Prescribing is limited to doctors on the GMC Specialist Register, and any use must follow the Human Medicines Regulations 2012.

Clinical Bottom Line

Cannabis-based products are not approved for dementia in the UK.

Early research shows possible improvements in sleep and agitation, but findings are limited.

NICE and NHS England advise specialist oversight and careful monitoring.

Long-term safety and cognitive outcomes remain uncertain.

Only GMC-registered clinicians may prescribe under full regulatory compliance.

Role Of AlleviMed

Educational services such as AlleviMed provide clear information about the UK’s regulated approach to medical cannabis. They help patients and families understand how eligibility and safety standards work but do not issue prescriptions or recommend treatment. For caregivers exploring this topic, AlleviMed can clarify what is currently known, and not yet proven, about cannabis and sleep in dementia.

Takeaway

While some dementia caregivers have observed calmer nights and better sleep with supervised cannabis use, national regulators remain cautious. Evidence is promising but preliminary, and cannabis is not yet an approved treatment for sleep problems in dementia. Patients and families should always seek advice from qualified specialists before considering any unlicensed medicine.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.